The science and technology innovation board Journal reporter noted that over the past year, a number of semiconductor companies have indeed terminated the IPO process. For example, Chengdu Ruiyuan Semiconductor Technology Co., Ltd. terminated its IPO nearly 10 months after the meeting. In addition, more than 20 companies in the semiconductor industry also voluntarily withdrew their materials to terminate the IPO after being inspected on the spot.Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.
Unlike Shenzhen and Anhui, which made good use of "green channel" policies such as debt financing, mergers and acquisitions, and vigorously developed equity-based M&A funds, this time Shanghai directly gave the scale of M&A funds."Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."Unlike Shenzhen and Anhui, which made good use of "green channel" policies such as debt financing, mergers and acquisitions, and vigorously developed equity-based M&A funds, this time Shanghai directly gave the scale of M&A funds.
Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures."Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."